Melior Discovery

Melior Discovery is a biotechnology company that specializes in phenotypic screening for drug discovery and repositioning. The company was founded in 2005 and is based in Exton, Pennsylvania.

History

Melior Discovery was established with the aim of revolutionizing the process of drug discovery. The company's founders recognized the potential of phenotypic screening in identifying new therapeutic uses for existing drugs, a process known as drug repositioning.

Services

Melior Discovery offers a range of services to support drug discovery and development. These include:

• Phenotypic Screening: Melior Discovery uses its proprietary theraTRACE® platform to conduct phenotypic screening. This platform allows for the simultaneous evaluation of multiple disease models, increasing the efficiency of drug discovery and repositioning.

• In Vivo Pharmacology: The company provides in vivo pharmacology services to evaluate the efficacy of drug candidates in animal models of disease.

• Drug Repositioning: Melior Discovery's drug repositioning services aim to identify new therapeutic uses for existing drugs, potentially reducing the time and cost of drug development.

Partnerships

Melior Discovery has formed partnerships with a number of pharmaceutical and biotechnology companies to support their drug discovery and development efforts. These partnerships leverage Melior Discovery's expertise in phenotypic screening and in vivo pharmacology.

See Also

• Phenotypic Screening
• Drug Discovery
• Drug Repositioning
• In Vivo Pharmacology

References

<references />

   This article is a biotechnology stub. You can help WikiMD by expanding it!

• 
  Melior Discovery Logo